Product image of Lipantil Micro (Fenofibrate) supplied by GNH India

Lipantil Micro

Active Ingredient:
Fenofibrate
Origin:
EU

Lipantil Micro (Fenofibrate)

Fenofibrate, the active ingredient in Lipantil Micro, is a fibrate‑class lipid‑lowering agent presented as an oral tablet for oral administration. It is indicated for the management of elevated triglyceride and cholesterol levels in adult patients with various forms of dyslipidaemia.

GNH India supplies Lipantil Micro as a licensed, Good Distribution Practice‑compliant pharmaceutical product, providing reliable global sourcing for hospitals, pharmacies and clinical centres worldwide, with consistent quality and regulatory compliance across EU markets, and a track record of timely delivery.

Manufacturer / TM Owner

Mylan Ire Healthcare Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Fenofibrate acts on lipid metabolism pathways to reduce elevated blood lipids.

  • Hypertriglyceridemia: reduces triglyceride levels and associated cardiovascular risk.
  • Mixed dyslipidemia: lowers triglycerides and modestly improves HDL cholesterol.
  • Hypercholesterolemia: decreases total and LDL cholesterol concentrations.

How It Works

  • Fenofibrate activates peroxisome proliferator‑activated receptor‑alpha (PPARα) in hepatic cells, increasing transcription of genes that promote fatty‑acid oxidation, lipoprotein lipase synthesis and apolipoprotein modulation. This accelerates catabolism of triglyceride‑rich lipoproteins, raises HDL‑cholesterol, and reduces hepatic VLDL and LDL production, improving the overall plasma lipid profile.

Side Effects

Fenofibrate may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
  • Elevated liver enzymes: transient increase in ALT or AST.
  • Muscle pain: mild myalgia without weakness.
  • Headache: occasional tension‑type headache.

Serious or Rare Side Effects

  • Rhabdomyolysis: severe muscle breakdown with possible renal impairment.
  • Hepatotoxicity: significant liver injury or jaundice.
  • Severe allergic reactions: rash, angioedema or anaphylaxis.
  • Gallbladder disease: cholelithiasis or biliary colic.

Precautions & Warnings

When prescribing fenofibrate, clinicians should consider several safety and handling precautions.

  • Liver function: assess baseline hepatic enzymes and monitor periodically.
  • Renal function: evaluate kidney status, especially in patients with impairment.
  • Muscle disorders: avoid in patients with active myopathy or recent rhabdomyolysis.
  • Drug interactions: review concomitant medications that affect statin metabolism.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Avoid Interactions

Fenofibrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Statins (especially high‑dose simvastatin): increased risk of myopathy or rhabdomyolysis.
  • Anticoagulants (warfarin): potentiation of anticoagulant effect, requiring INR monitoring.
  • Bile acid sequestrants: may reduce fenofibrate absorption, diminishing lipid‑lowering effect.

Moderate Interactions (Monitor Closely)

  • CYP2C8 inhibitors (e.g., gemfibrozil): increased fenofibrate plasma levels.
  • Immunosuppressants (e.g., cyclosporine): may raise fenofibrate concentrations.
  • Thyroid hormones: fenofibrate may affect thyroid function tests.

Frequently Asked Questions

Lipantil Micro contains fenofibrate, which is prescribed to lower elevated triglyceride and cholesterol levels in adults with hypertriglyceridemia, mixed dyslipidemia, or hypercholesterolemia. It helps reduce cardiovascular risk associated with abnormal lipid profiles.

Fenofibrate activates the nuclear receptor PPARα, leading to increased expression of genes that enhance fatty‑acid oxidation and lipoprotein lipase activity. This accelerates clearance of triglyceride‑rich particles, raises HDL‑cholesterol, and lowers VLDL and LDL production.

The dosage of fenofibrate is individualized by the prescribing clinician based on the patient’s lipid profile, renal function, and overall health status. Only a qualified healthcare professional should determine the appropriate strength and frequency.

Safety data for fenofibrate during pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To request Lipantil Micro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to fenofibrate is the statin class, which primarily lowers LDL‑cholesterol. Fenofibrate is more effective at reducing triglycerides and modestly raising HDL‑cholesterol, making it a preferred option when hypertriglyceridaemia is the dominant concern.

Store Lipantil Micro at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Lipantil Micro is taken orally, usually once daily with a meal to improve absorption. Patients should follow the prescribing clinician’s instructions regarding timing and whether it should be taken with food or on an empty stomach.

The most serious adverse events include rhabdomyolysis (severe muscle breakdown), significant liver injury, and rare severe allergic reactions such as anaphylaxis. Patients should report unexplained muscle pain, dark urine, jaundice, or rash promptly to their healthcare provider.

Fenofibrate is contraindicated in patients with severe liver disease, active gallbladder disease, known hypersensitivity to fenofibrate or other fibrates, and in individuals with a history of rhabdomyolysis. Caution is also advised for those with renal impairment or uncontrolled hypothyroidism.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fenofibrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT